UBS Group reaffirmed their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a research report released on Tuesday, The Fly reports.
GSK has been the subject of a number of other reports. Credit Suisse Group downgraded GlaxoSmithKline from a neutral rating to an underperform rating in a research note on Wednesday, January 20th. Berenberg Bank restated a buy rating on shares of GlaxoSmithKline in a research note on Thursday, February 11th. Deutsche Bank Aktiengesellschaft downgraded GlaxoSmithKline from a hold rating to a sell rating in a research note on Wednesday, February 3rd. SVB Leerink restated a market perform rating on shares of GlaxoSmithKline in a research note on Monday, March 29th. Finally, Morgan Stanley restated an equal weight rating on shares of GlaxoSmithKline in a research note on Friday, February 12th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company. GlaxoSmithKline has a consensus rating of Hold and an average target price of $40.00.
NYSE:GSK opened at $37.70 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.61 and a current ratio of 0.90. The company has a market cap of $101.51 billion, a PE ratio of 11.60, a PEG ratio of 2.93 and a beta of 0.67. GlaxoSmithKline has a 52-week low of $33.26 and a 52-week high of $43.18. The stock has a 50-day simple moving average of $36.04 and a 200 day simple moving average of $36.54.
The company also recently declared a quarterly dividend, which was paid on Thursday, April 8th. Investors of record on Friday, February 19th were issued a dividend of $0.628 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.51 annualized dividend and a yield of 6.66%. The ex-dividend date of this dividend was Thursday, February 18th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 79.50%.
A number of large investors have recently added to or reduced their stakes in GSK. Kathmere Capital Management LLC acquired a new stake in GlaxoSmithKline during the 4th quarter worth approximately $29,000. Concord Wealth Partners acquired a new stake in GlaxoSmithKline during the 4th quarter worth approximately $29,000. ADE LLC acquired a new position in GlaxoSmithKline in the 4th quarter valued at $30,000. Key Financial Inc acquired a new position in GlaxoSmithKline in the 4th quarter valued at $31,000. Finally, Fieldpoint Private Securities LLC acquired a new position in GlaxoSmithKline in the 4th quarter valued at $34,000. 11.83% of the stock is owned by institutional investors and hedge funds.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Recommended Story: Market Timing – The Benefits and the Danger
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.